Miyako Satouchi

List of Publications by Year
in descending order

24 papers	5,400 citations	687363 13 h-index	580821 25 g-index
25 all docs	25 docs citations	25 times ranked	5513 citing authors

#	Article	IF	Citations
1	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncology, The, 2010, 11, 121-128.	10.7	3,794
2	Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet, The, 2017, 390, 29-39.	13.7	753
3	Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Nonâ€“Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105. Journal of Clinical Oncology, 2010, 28, 3739-3745.	1.6	261
4	Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-NaÃ¯ve Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study. Journal of Clinical Oncology, 2010, 28, 5240-5246.	1.6	161
5	Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 2020, 139, 195-199.	2.0	100
6	Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).. Journal of Clinical Oncology, 2012, 30, 7521-7521.	1.6	71
7	Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer, 2013, 81, 97-101.	2.0	42
8	Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer. Lung Cancer, 2017, 105, 23-30.	2.0	30
9	The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease. Japanese Journal of Clinical Oncology, 2018, 48, 89-93.	1.3	27
10	Osimertinib for Japanese patients with T790Mâ€positive advanced nonâ€smallâ€cell lung cancer: A pooled subgroup analysis. Cancer Science, 2019, 110, 2884-2893.	3.9	22
11	A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). Lung Cancer, 2015, 87, 136-140.	2.0	16
12	A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110). Lung Cancer, 2015, 89, 146-153.	2.0	16
13	Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas Â® EGFR mutation test. Lung Cancer, 2017, 111, 190-194.	2.0	13
14	Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations. Lung Cancer, 2018, 124, 65-70.	2.0	13
15	A Phase II Study of Pemetrexed in Chemotherapy-naive Elderly Patients Aged >=75 years with Advanced Non-squamous Non-small-cell Lung Cancer (HANSHIN Oncology Group 003). Japanese Journal of Clinical Oncology, 2013, 43, 1184-1189.	1.3	10
16	Phase 2 study of Sâ€1 and carboplatin plus bevacizumab followed by maintenance Sâ€1 and bevacizumab for chemotherapyâ€naive patients with advanced nonsquamous nonâ€small cell lung cancer. Cancer, 2013, 119, 2275-2281.	4.1	9
17	Pemetrexed monotherapy for chemo-naÃ¯ve elderly (aged â‰¥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and) Tj ETQq1 1 0.784314 rgBT /Ove	2.3	6
18	A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naÃ¯ve patients with advanced non-small-cell lung cancer. BMC Cancer, 2020, 20, 115.	2.6	6

#	Article	IF	Citations
19	Antiâ€“cytotoxic T-lymphocyteâ€“associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. Lung Cancer, 2021, 159, 162-170.	2.0	6
20	Firstâ€line pembrolizumab vs chemotherapy in metastatic nonâ€smallâ€cell lung cancer: KEYNOTEâ€024 Japan subset*. Cancer Science, 2021, 112, 5000-5010.	3.9	6
21	Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged â‰¥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. Translational Lung Cancer Research, 2020, 9, 459-470.	2.8	5
22	The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients. Respiratory Investigation, 2020, 58, 269-274.	1.8	5
23	Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study. Respiratory Investigation, 2016, 54, 334-340.	1.8	4
24	A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001). Cancer Chemotherapy and Pharmacology, 2014, 73, 17-23.	2.3	2